Fox Run Management L.L.C. Takes $688,000 Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Fox Run Management L.L.C. bought a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 18,526 shares of the company's stock, valued at approximately $688,000.

Other large investors have also recently made changes to their positions in the company. Pacer Advisors Inc. grew its holdings in shares of Amphastar Pharmaceuticals by 51,977.4% during the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after buying an additional 1,347,775 shares in the last quarter. Wellington Management Group LLP purchased a new stake in Amphastar Pharmaceuticals during the 3rd quarter valued at about $957,000. XTX Topco Ltd acquired a new stake in Amphastar Pharmaceuticals in the 3rd quarter valued at about $674,000. Geode Capital Management LLC lifted its stake in Amphastar Pharmaceuticals by 1.5% in the 3rd quarter. Geode Capital Management LLC now owns 920,363 shares of the company's stock worth $44,674,000 after purchasing an additional 14,015 shares in the last quarter. Finally, Glenmede Trust Co. NA boosted its holdings in shares of Amphastar Pharmaceuticals by 145.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 37,884 shares of the company's stock worth $1,839,000 after purchasing an additional 22,439 shares during the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Trading Down 0.2 %

Amphastar Pharmaceuticals stock traded down $0.07 during midday trading on Friday, hitting $28.43. 386,842 shares of the stock were exchanged, compared to its average volume of 438,844. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The stock's 50-day simple moving average is $31.07 and its 200 day simple moving average is $39.96. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $25.89 and a fifty-two week high of $53.96. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of 9.48, a PEG ratio of 2.19 and a beta of 0.77.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, Piper Sandler cut their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Friday, March 21st.

Insider Activity

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the firm's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares of the company's stock, valued at $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 27.10% of the company's stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.